Memphasys Limited Logo

Memphasys Limited

MEM.AX

(1.0)
Stock Price

0,01 AUD

-35.74% ROA

-66.03% ROE

-4.16x PER

Market Cap.

10.116.737,00 AUD

64.69% DER

0% Yield

-7403.37% NPM

Memphasys Limited Stock Analysis

Memphasys Limited Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Memphasys Limited Fundamental Stock Analysis
# Analysis Rating
1 PBV

The stock's PBV ratio (1.08x) reflects a fair valuation, making it an attractive option for investors seeking balanced opportunities.

2 DER

The stock maintains a fair debt to equity ratio (73%), indicating a reasonable balance between the money it owes and the ownership it possesses.

3 Assets Growth

With a track record of continuous revenue growth in the last three years, this company offers a promising investment opportunity

4 Graham Number

The Graham number calculation reveals that this company's stock price is potentially underestimated, implying that it may be a promising investment option.

5 ROE

The stock's ROE indicates a negative return (-31.15%) on shareholders' equity, suggesting poor financial performance.

6 ROA

The stock's ROA (-56.99%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment.

7 Revenue Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

8 Net Profit Growth

Over the past five years, this company's net profit has failed to exhibit any growth, indicating a stagnant financial performance and making it a less favorable choice for potential investors.

9 Dividend Growth

Potential investors should be aware that the company's dividend growth has shown no upward trend in the past three years, indicating limited potential for increased returns.

10 Dividend

The company's lack of dividends in the past three years may concern investors seeking regular income.

11 Buffet Intrinsic Value

Warren Buffett's formula suggests that the company's stock is overpriced (0), presenting a possible disadvantage for investors as its market price surpasses its estimated intrinsic value.

Memphasys Limited Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Memphasys Limited Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Sell
3 RSI Hold
4 Stoch RSI Hold

Memphasys Limited Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Memphasys Limited Revenue
Year Revenue Growth
2008 1.610.892
2009 2.167.181 25.67%
2010 5.374.458 59.68%
2011 1.799.710 -198.63%
2012 2.549.415 29.41%
2013 918.654 -177.52%
2014 850.855 -7.97%
2015 79.900 -964.9%
2016 63.960 -24.92%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2020 0 0%
2021 211.483 100%
2022 27.148 -679%
2023 15.371 -76.62%
2024 96.000 83.99%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Memphasys Limited Research and Development Expenses
Year Research and Development Expenses Growth
2008 2.520.465
2009 0 0%
2010 5.520 100%
2011 404.438 98.64%
2012 900.720 55.1%
2013 864.242 -4.22%
2014 513.852 -68.19%
2015 207.706 -147.39%
2016 178.573 -16.31%
2017 137.594 -29.78%
2018 181.109 24.03%
2019 196.901 8.02%
2020 113.288 -73.81%
2020 113.288 0%
2021 466.264 75.7%
2022 1.089.366 57.2%
2023 1.469.294 25.86%
2024 5.752.908 74.46%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Memphasys Limited General and Administrative Expenses
Year General and Administrative Expenses Growth
2008 1.932.018
2009 1.067.604 -80.97%
2010 535.455 -99.38%
2011 2.281.256 76.53%
2012 1.390.565 -64.05%
2013 1.579.473 11.96%
2014 796.726 -98.25%
2015 1.509.329 47.21%
2016 1.659.341 9.04%
2017 1.971.689 15.84%
2018 986.781 -99.81%
2019 886.955 -11.25%
2020 1.148.440 22.77%
2020 1.148.440 0%
2021 1.235.249 7.03%
2022 439.546 -181.03%
2023 570.797 22.99%
2024 0 0%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Memphasys Limited EBITDA
Year EBITDA Growth
2008 -5.231.965
2009 -992.022 -427.4%
2010 3.403.700 129.15%
2011 567 -600199.82%
2012 -1.518.216 100.04%
2013 -2.273.031 33.21%
2014 -1.066.991 -113.03%
2015 -1.617.398 34.03%
2016 -1.754.508 7.81%
2017 -2.088.579 16%
2018 -1.146.940 -82.1%
2019 -1.074.940 -6.7%
2020 -1.133.879 5.2%
2020 -1.065.500 -6.42%
2021 -1.434.020 25.7%
2022 -2.583.720 44.5%
2023 -3.020.980 14.47%
2024 -9.422.000 67.94%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Memphasys Limited Gross Profit
Year Gross Profit Growth
2008 127.905
2009 1.047.660 87.79%
2010 4.452.555 76.47%
2011 1.115.159 -299.28%
2012 1.604.883 30.51%
2013 55.722 -2780.16%
2014 150.461 62.97%
2015 21.906 -586.85%
2016 44.514 50.79%
2017 -20.697 315.07%
2018 -20.954 1.23%
2019 -8.920 -134.91%
2020 0 0%
2020 -196.231 100%
2021 -48.004 -308.78%
2022 -922.599 94.8%
2023 -824.861 -11.85%
2024 -2.366.328 65.14%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Memphasys Limited Net Profit
Year Net Profit Growth
2008 -5.496.190
2009 -2.739.043 -100.66%
2010 3.291.709 183.21%
2011 -6.563.463 150.15%
2012 -4.924.039 -33.29%
2013 -1.841.920 -167.33%
2014 -3.842.140 52.06%
2015 -2.360.019 -62.8%
2016 -2.174.721 -8.52%
2017 -1.999.891 -8.74%
2018 -401.159 -398.53%
2019 -1.044.578 61.6%
2020 -1.133.879 7.88%
2020 -1.133.879 0%
2021 -1.486.432 23.72%
2022 -2.081.964 28.6%
2023 -3.402.618 38.81%
2024 -8.558.024 60.24%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Memphasys Limited Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2008 -31
2009 -7 -416.67%
2010 1 0%
2011 -1 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2024 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Memphasys Limited Free Cashflow
Year Free Cashflow Growth
2008 -4.096.538
2009 -1.732.315 -136.48%
2010 -3.827.976 54.75%
2011 -3.889.188 1.57%
2012 -3.060.024 -27.1%
2013 -2.679.037 -14.22%
2014 -1.107.944 -141.8%
2015 -2.440.509 54.6%
2016 -1.275.661 -91.31%
2017 -1.893.328 32.62%
2018 -740.824 -155.57%
2019 -721.174 -2.72%
2020 -3.017.502 76.1%
2021 -2.956.843 -2.05%
2022 -2.611.295 -13.23%
2023 -3.228.701 19.12%
2024 -2.441.892 -32.22%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Memphasys Limited Operating Cashflow
Year Operating Cashflow Growth
2008 -3.998.047
2009 400.615 1097.98%
2010 -2.628.865 115.24%
2011 -1.696.642 -54.95%
2012 -655.087 -158.99%
2013 -987.970 33.69%
2014 -941.638 -4.92%
2015 -2.422.179 61.12%
2016 -1.270.580 -90.64%
2017 -1.228.595 -3.42%
2018 -738.419 -66.38%
2019 -707.472 -4.37%
2020 120.195 688.6%
2021 47.249 -154.39%
2022 311.817 84.85%
2023 -1.406.669 122.17%
2024 -2.590.514 45.7%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Memphasys Limited Capital Expenditure
Year Capital Expenditure Growth
2008 98.491
2009 2.132.930 95.38%
2010 1.199.111 -77.88%
2011 2.192.546 45.31%
2012 2.404.937 8.83%
2013 1.691.067 -42.21%
2014 166.306 -916.84%
2015 18.330 -807.29%
2016 5.081 -260.76%
2017 664.733 99.24%
2018 2.405 -27539.63%
2019 13.702 82.45%
2020 3.137.697 99.56%
2021 3.004.092 -4.45%
2022 2.923.112 -2.77%
2023 1.822.032 -60.43%
2024 -148.622 1325.95%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Memphasys Limited Equity
Year Equity Growth
2008 1.101.357
2009 -398.471 376.4%
2010 12.843.038 103.1%
2011 6.995.083 -83.6%
2012 4.562.379 -53.32%
2013 6.990.106 34.73%
2014 -992.848 804.05%
2015 746.591 232.98%
2016 1.477.651 49.47%
2017 -402.240 467.36%
2018 3.351.580 112%
2019 6.071.441 44.8%
2020 9.755.760 37.77%
2021 8.606.990 -13.35%
2022 7.646.534 -12.56%
2023 7.384.689 -3.55%
2024 6.837.755 -8%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Memphasys Limited Assets
Year Assets Growth
2008 5.055.784
2009 5.756.596 12.17%
2010 17.717.066 67.51%
2011 10.571.264 -67.6%
2012 8.951.867 -18.09%
2013 13.632.034 34.33%
2014 7.102.391 -91.94%
2015 6.844.468 -3.77%
2016 7.194.478 4.86%
2017 7.301.690 1.47%
2018 4.217.173 -73.14%
2019 6.836.438 38.31%
2020 11.298.641 39.49%
2021 14.580.839 22.51%
2022 14.121.129 -3.26%
2023 14.667.841 3.73%
2024 12.430.147 -18%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Memphasys Limited Liabilities
Year Liabilities Growth
2008 3.954.427
2009 6.155.067 35.75%
2010 4.874.028 -26.28%
2011 3.576.181 -36.29%
2012 4.389.488 18.53%
2013 6.641.928 33.91%
2014 8.095.239 17.95%
2015 6.097.877 -32.76%
2016 5.716.827 -6.67%
2017 7.703.930 25.79%
2018 865.593 -790.02%
2019 764.997 -13.15%
2020 1.542.881 50.42%
2021 5.973.849 74.17%
2022 6.474.595 7.73%
2023 7.283.152 11.1%
2024 5.592.392 -30.23%

Memphasys Limited Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0
Net Income per Share
-0
Price to Earning Ratio
-4.16x
Price To Sales Ratio
168.61x
POCF Ratio
-5.72
PFCF Ratio
-2.61
Price to Book Ratio
2.7
EV to Sales
243.3
EV Over EBITDA
-3.23
EV to Operating CashFlow
-4.52
EV to FreeCashFlow
-3.77
Earnings Yield
-0.24
FreeCashFlow Yield
-0.38
Market Cap
0,01 Bil.
Enterprise Value
0,01 Bil.
Graham Number
0.01
Graham NetNet
-0

Income Statement Metrics

Net Income per Share
-0
Income Quality
0.73
ROE
-0.66
Return On Assets
-0.36
Return On Capital Employed
-0.73
Net Income per EBT
1
EBT Per Ebit
0.85
Ebit per Revenue
-87.31
Effective Tax Rate
0

Margins

Sales, General, & Administrative to Revenue
5.34
Research & Developement to Revenue
35.64
Stock Based Compensation to Revenue
0.26
Gross Profit Margin
-27.09
Operating Profit Margin
-87.31
Pretax Profit Margin
-74.03
Net Profit Margin
-74.03

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0
Free CashFlow per Share
-0
Capex to Operating CashFlow
-0.2
Capex to Revenue
10.64
Capex to Depreciation
0.89
Return on Invested Capital
-0.47
Return on Tangible Assets
-0.36
Days Sales Outstanding
0
Days Payables Outstanding
112.93
Days of Inventory on Hand
35.69
Receivables Turnover
0
Payables Turnover
3.23
Inventory Turnover
10.23
Capex per Share
0

Balance Sheet

Cash per Share
0,00
Book Value per Share
0,00
Tangible Book Value per Share
0
Shareholders Equity per Share
0
Interest Debt per Share
0
Debt to Equity
0.65
Debt to Assets
0.36
Net Debt to EBITDA
-0.99
Current Ratio
0.31
Tangible Asset Value
0,01 Bil.
Net Current Asset Value
0,00 Bil.
Invested Capital
-2927676
Working Capital
0,00 Bil.
Intangibles to Total Assets
0
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
152899
Debt to Market Cap
0.44

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Memphasys Limited Dividends
Year Dividends Growth

Memphasys Limited Profile

About Memphasys Limited

Memphasys Limited develops, manufactures, and sells cell and protein separation devices, and related consumables for the healthcare, veterinary, and biotechnology market sectors in Australia. It primarily develops Felix, a novel automated device for quickly and gently separating high quality sperm from a raw semen sample for use in human IVF procedures. In addition, the company's product pipeline include ROSA, a rapid oxidative stress assay; Samson Device, rapid equine pregnancy prediction assay; SemPort, a central lab human semen analysis from distantly located donors; and AI-Port. An ambient temperature semen transport device used for animal artificial insemination. Memphasys Limited was formerly known as NuSep Holdings Limited and changed its name to Memphasys Limited in July 2016. The company was incorporated in 2006 and is based in Homebush, Australia.

CEO
Dr. David Ali
Employee
24
Address
30 Richmond Road
Homebush, 2140

Memphasys Limited Executives & BODs

Memphasys Limited Executives & BODs
# Name Age
1 Dr. David Ali
Chief Executive Officer, MD & Executive Director
70
2 Mr. Pablo Neyertz
Director of Finance
70
3 Prof. R. John Aitken Ph.D., ScD FRSE
Scientific Director
70
4 Associate Prof. Hassan Bakos
Director of Operations
70

Memphasys Limited Competitors

PharmAust Limited Logo
PharmAust Limited

PAA.AX

(0.5)
Biotron Limited Logo
Biotron Limited

BIT.AX

(0.5)
Dimerix Limited Logo
Dimerix Limited

DXB.AX

(0.8)
Orthocell Limited Logo
Orthocell Limited

OCC.AX

(0.5)
Patrys Limited Logo
Patrys Limited

PAB.AX

(1.0)